BrightPath Biotherapeutics Co., Ltd. (TYO:4594)

Japan flag Japan · Delayed Price · Currency is JPY
82.00
+30.00 (57.69%)
Jul 4, 2025, 2:03 PM JST
43.86%
Market Cap 4.71B
Revenue (ttm) 1.13M
Net Income (ttm) -1.15B
Shares Out 90.49M
EPS (ttm) -14.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 107,959,600
Average Volume 9,299,170
Open 72.00
Previous Close 52.00
Day's Range 66.00 - 82.00
52-Week Range 32.00 - 89.00
Beta 1.28
RSI 74.21
Earnings Date Aug 8, 2025

About TYO:4594

BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan. It is developing GRN-1201, a cancer peptide vaccine candidate that is in Phase II clinical trials for the treatment of non-small cell lung cancer, as well as in Phase I clinical trials to treat melanoma. The company is also developing BP2201, a product candidate in Phase I clinical trials to target cancer antigens in various types of cancer; and BP2301, a product candidate in Phase I clinical trials for the treatment of solid tumors sarcoma a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 42
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4594
Full Company Profile

Financial Performance

In 2024, TYO:4594's revenue was 1.13 million, an increase of 1473.61% compared to the previous year's 72,000. Losses were -1.15 billion, -1.45% less than in 2023.

Financial Statements

News

There is no news available yet.